Coagulation Factor IX, Human Plasma

Native coagulation factor IX from human plasma. Sold on the basis of plasma equivalent units. 100 plasma equivalent units are equal to 500 µg of Factor IX. In vivo, activation of Factor IX to IXa occurs via either the tissue factor/Factor VIIa complex (the extrinsic pathway), or Factor XIa (the intrinsic pathway). Activated Factor IXa, in a complex with Factor VIIIa, can then convert Factor X to Xa, the catalytic component of the prothrombinase complex.

Native coagulation factor IX from human plasma. Sold on the basis of plasma equivalent units. 100 plasma equivalent units are equal to 500 µg of Factor IX. In vivo, activation of Factor IX to IXa occurs via either the tissue factor/Factor VIIa complex (the extrinsic pathway), or Factor XIa (the intrinsic pathway). Activated Factor IXa, in a complex with Factor VIIa, can then convert Factor X to Xa, the catalytic component of the prothrombinase complex.

Please refer to vial label for lot-specific concentration.

Toxicity: Standard Handling (A)

In 100 mM NaCl, 20 mM Tris-HCl, 1 mM benzamidine, pH 7.5.

Prepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.

Following initial thaw, aliquot and freeze (-70°C).

Clotting activity is determined by comparison to a standard curve produced using normal pooled human plasma

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.